Chief Executive Officer
AI
AevisBio, Inc
The startup specializes in targeted protein degradation (TPD) technology through its proprietary Cereblon Binding Modules (CBMs) and a Protein Degron Library (PDL), which enhance the specificity and safety of molecular glue therapeutics. This approach accelerates the identification of novel therapeutic targets for diseases associated with aging, ultimately improving patient outcomes for those with critical health conditions.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$8.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup specializes in targeted protein degradation (TPD) technology through its proprietary Cereblon Binding Modules (CBMs) and a Protein Degron Library (PDL), which enhance the specificity and safety of molecular glue therapeutics. This approach accelerates the identification of novel therapeutic targets for diseases associated with aging, ultimately improving patient outcomes for those with critical health conditions.